Back to BARCLAYS PLC BARCLAYS PLC

EFTREFTR
3 quarters

Position history for BARCLAYS PLCBARCLAYS PLC's holdings in EFFECTOR THERAPEUTICS INC

No. Barclays exited its EFTR (Effector Therapeutics) position in Q4 2024. Its Q3 2024 13F listed 100 shares worth $4. Barclays first reported EFTR in Q2 2024 and held it in 2 quarterly 13F filings.

Final Value

$0

Final Shares

0

Total Value Change

-$29

Total Shares Change

-100

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2024-Q4
Latest
Exited
0
-100.0%
$00.0%$0.04
0
2024-Q3
Unchanged
100
0.0%
$40.0%$0.04
0
2024-Q2
New
100
-
$290.0%$0.29
17

Other major holders of EFTR: Carlyle Group Inc., Ensign Peak Advisors, Inc, GEODE CAPITAL MANAGEMENT, LLC, UBS Group AG

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used